Company Summary - BioCryst (BCRX) is currently an intriguing investment choice due to solid earnings estimate revision activity and a favorable Zacks Rank [1][3] - Over the past month, current quarter estimates improved from a loss of $0.09 per share to a loss of $0.07 per share, while current year estimates increased from a loss of $0.07 per share to a loss of $0.06 per share [4] Industry Summary - The Medical – Drugs industry has a Zacks Industry Rank of 75 out of more than 250 industries, indicating strong positioning compared to other segments [2] - The positive trends in the Medical – Drugs space suggest that a rising tide may benefit multiple securities within the industry [2][5]

RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 9:30 a.m. ET. Link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst's website at http://www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology compa ...

Group 1 - BioCryst Pharmaceuticals reported revenue of $131.53 million for the quarter ended December 2024, representing a 40.8% increase year-over-year [1] - The earnings per share (EPS) for the quarter was -$0.13, an improvement from -$0.28 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $130.8 million by 0.56%, while the EPS fell short of the consensus estimate of -$0.06 by 116.67% [1] Group 2 - BioCryst's revenue from ORLADEYO in the U.S. was $106.97 million, slightly above the average estimate of $106.61 million [4] - The revenue from ORLADEYO outside the U.S. was $17.21 million, surpassing the average estimate of $14.10 million [4] - Total revenue from ORLADEYO was $124.19 million, compared to the estimated $121.30 million, marking a 36.6% increase from the previous year [4] Group 3 - Over the past month, BioCryst shares have returned +4.2%, contrasting with a -2.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Core Viewpoint - BioCryst Pharmaceuticals (BCRX) has experienced a decline of 11.5% over the past week, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottoming out, suggesting that selling pressure may be exhausting [2][4]. - A hammer pattern forms when there is a small candle body with a long lower wick, typically occurring during a downtrend, signaling that bears may be losing control [3][4]. - This pattern can appear on various timeframes and is utilized by both short-term and long-term investors [4]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for BCRX, which is a bullish indicator for the stock [6]. - The consensus EPS estimate for the current year has increased by 18.4% over the last 30 days, indicating that analysts expect better earnings than previously predicted [7]. - BCRX holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [8].

BioCryst Pharmaceuticals (BCRX) closed the last trading session at $8.28, gaining 4.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.25 indicates an 84.2% upside potential.The average comprises 12 short-term price targets ranging from a low of $8 to a high of $30, with a standard deviation of $6.48. While the lowest estimate indicates a decline of 3.4% from the current price ...

Group 1 - The biotech sector has experienced significant volatility, with investors often focusing on hyped plays rather than long-term winners [1] - BioCryst Pharmaceuticals is highlighted as a strong player in the rare disease market that has not yet received adequate market recognition [1] - The approach to investment in high-growth companies involves a combination of fundamental analysis and future trend prediction, emphasizing the potential of innovation for substantial returns [1]

After working as a Registered Nurse for several years, I transitioned into financial analysis, earning my MBA and developing expertise in healthcare & technology investments. Since 2017, I've published investment analyses on Seeking Alpha, focusing on thorough valuation modeling. My approach centers on examining core assumptions that drive stock valuations, particularly through detailed discounted cash flow analysis. I provide readers with various scenarios to help them understand potential outcomes. The pr ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Back in November 2023, I published a note on BioCryst (NASDAQ: BCRX ) to Seeking Alpha, assigning its stock a "Sell" rating. At the time, shares were priced at $5.5, and in ...

Financial Performance - Revenues for 2024 reached $450.7 million, a 36% increase from $331.4 million in 2023[459]. - Total operating expenses for 2024 were $453.3 million, compared to $435.1 million in 2023, reflecting a slight increase of 4%[459]. - The net loss for 2024 was $88.9 million, significantly improved from a net loss of $226.5 million in 2023[459]. - The balance of accumulated deficit as of December 31, 2024, was $1.77 billion, an increase from $1.68 billion in 2023[474]. - The company reported a loss before provision for income taxes of $86,954,000 in 2024, a decrease from $226,229,000 in 2023 and $244,383,000 in 2022[620]. - The company's effective tax rate for 2024 resulted in an income tax expense of $1,927,000, significantly lower than $310,000 in 2023 and $2,733,000 in 2022[620]. Cash and Assets - Cash and cash equivalents decreased to $104.7 million in 2024 from $110.6 million in 2023, a decline of approximately 5%[462]. - Total assets decreased to $490.4 million in 2024 from $517.0 million in 2023, a reduction of about 5%[457]. - The total investments maturing in one year or less decreased to $216,137,000 in 2024 from $278,344,000 in 2023, a decline of approximately 22%[545]. - As of December 31, 2024, the total assets measured at fair value were $236,460,000, a decrease from $278,344,000 in 2023, representing a decline of approximately 15%[543]. Expenses - Research and development expenses for 2024 were $174.6 million, down from $216.6 million in 2023, a decrease of 19%[459]. - Selling, general and administrative expenses increased to $266.1 million in 2024, up from $213.9 million in 2023, an increase of 24%[459]. - The Company recorded a depreciation expense of $1,246,000 for the year ended December 31, 2024, compared to $1,655,000 in 2023[551]. - Operating lease expense for the year ended December 31, 2024 was $2,301, an increase from $2,018 in 2023 and $1,578 in 2022[591]. Revenue Sources - Product sales, net for 2024 reached $442.7 million, up from $324.7 million in 2023, reflecting a 36% growth[473]. - ORLADEYO revenues in the U.S. reached $386.0 million in 2024, up 34% from $288.4 million in 2023[539]. - The company recorded total ORLADEYO revenues of $437.7 million in 2024, compared to $326.0 million in 2023, reflecting a 34% year-over-year growth[539]. - Collaborative and other revenues for 2024 were $8.0 million, an increase from $6.7 million in 2023[473]. Debt and Financing - The company reported an effective interest rate of 13.14% on the $300.0 million borrowing under the Pharmakon Loan Agreement for the year ended December 31, 2024[448]. - As of December 31, 2024, total borrowings under the Pharmakon Loan Agreement amounted to $323.7 million, including $10.041 million capitalized as Pharmakon PIK Interest Payments[578]. - The Company had total borrowings of $300 million under the Pharmakon Loan Agreement as of December 31, 2023, with interest expense of $27.326 million for that year[579]. - The effective interest rate on the Athyrium Term Loans was 13.71% for the year ended December 31, 2023, compared to 12.87% for the previous year[586]. Strategic Focus - The company is focused on the commercialization of ORLADEYO® (berotralstat) and anticipates potential government stockpiling orders for its products[14]. - The company is implementing strategic plans for its business and product candidates, focusing on best-in-class and first-in-class medicines[14]. - The company continues to evaluate opportunities for funding future operations, including out-licensing and government funding[469]. Risks and Compliance - The company relies heavily on third parties for product development and commercialization, which could materially impact its financial condition if these relationships fail[20]. - The company faces intense competition, which could reduce demand for its products if it fails to compete effectively[22]. - The company is subject to various laws and regulations, and non-compliance could result in substantial penalties and harm to its reputation[22]. - The company has recorded a valuation allowance against substantially all potential tax assets due to uncertainties in utilizing deferred tax assets[520]. Stock and Compensation - The Company’s stock-based compensation expense for 2024 was $65.4 million, compared to $55.6 million in 2023[474]. - The weighted average grant date fair value of restricted stock unit awards granted during 2024 was $7.32, up from $6.71 in 2023[607]. - Total stock-based compensation expense for the year ended December 31, 2024 was $65,413, up from $55,615 in 2023 and $44,701 in 2022[601]. - The total intrinsic value of stock option awards exercised under the Incentive Plan was $3,601 for the year ended December 31, 2023, compared to $21,150 in 2022[606].

Investors clearly weren't in a forgiving mood on Monday when it came to BioCryst Pharmaceuticals (BCRX -9.99%) stock. After the commercial-stage biotech published its fourth-quarter and full-year 2024 results, they traded its shares down by an even 10% on the day. That fall was far steeper than the 0.5% slip of the benchmark S&P 500 (^GSPC -0.50%).A mixed final quarter of 2024For the quarter, BioCryst managed to increase its revenue by 41% to $131.5 million. The company also narrowed its generally accepted ...